{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:52:26Z","timestamp":1789426346194,"version":"build-2803163510"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>We present one of the largest cohorts of <jats:italic toggle=\"yes\">TP53<\/jats:italic>-pathogenic germline variants (PGVs) associated with patients with Li-Fraumeni syndrome (n = 82) with breast tumors (19 to 76\u00a0y; median age: 35). Most had missense variants (77%), followed by large gene rearrangements (LGRs; 12%), truncating (6%), and splice-site (5%) variants. Twenty-one unique germline missense variants were found, with hotspots at codons 175, 181, 245, 248, 273, 334, and 337. Of 100 total breast tumors, 63% were invasive (mostly ductal), 30% pure ductal carcinoma in situ, 4% fibroepithelial lesions, and 3% with unknown histology. Unlike <jats:italic toggle=\"yes\">BRCA<\/jats:italic>-associated tumors, approximately half of the breast cancers exhibited <jats:italic toggle=\"yes\">HER2<\/jats:italic>-positivity, of which ~50% showed estrogen receptor coexpression. Pathology slides were available for review for 61 tumors (44 patients), and no significant correlation between the type of <jats:italic toggle=\"yes\">TP53<\/jats:italic> PGVs and histologic features was noted. High p53 immunohistochemistry expression (&gt;50%) was seen in 67% of tumors tested (mostly missense variant). Null pattern (&lt;1% cells) was seen in 2 (LGR and splicing variants carriers). Surprisingly, 2 tumors from patients with an LGR and 1 tumor from a patient with a truncating variant showed p53 overexpression (&gt;50%). The subset of patients with the Brazilian p.R337H variant presented at a higher age than those with non-p.R337H variant (46 vs 35\u00a0y) though statistically insignificant (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.071) due to an imbalance in the sample size, and were uniquely negative for <jats:italic toggle=\"yes\">HER2<\/jats:italic>-overexpressing tumors. To conclude, breast cancer in carriers of <jats:italic toggle=\"yes\">TP53<\/jats:italic> PGVs has some unique clinicopathological features that suggest differential mechanisms of tumor formation. p53 immunohistochemistry cannot be used as a surrogate marker to identify germline <jats:italic toggle=\"yes\">TP53<\/jats:italic>-mutated breast cancers.<\/jats:p>","DOI":"10.1097\/pas.0000000000002338","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T13:00:08Z","timestamp":1733317208000},"page":"195-205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Clinicopathologic Features of Breast Tumors in Germline TP53 Variant\u2013Associated Li-Fraumeni Syndrome"],"prefix":"10.1097","volume":"49","author":[{"given":"Mohan","family":"Narasimhamurthy","sequence":"first","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabamita","family":"Boruah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renyta","family":"Moses","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Bleiweiss","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara N.","family":"Maxwell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, University of Pennsylvania Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupma","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"R1-20250219","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer p53, Guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"R2-20250219","doi-asserted-by":"crossref","first-page":"D962","DOI":"10.1093\/nar\/gks1033","article-title":"The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis","volume":"41","author":"Leroy","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"R3-20250219","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-71-4-747","article-title":"Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?","volume":"71","author":"Li","year":"1969","journal-title":"Ann Intern Med"},{"key":"R4-20250219","first-page":"5358","article-title":"A cancer family syndrome in twenty-four kindreds","volume":"48","author":"Li","year":"1988","journal-title":"Cancer Res"},{"key":"R5-20250219","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms [published correction appears in science","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"R6-20250219","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/348747a0","article-title":"Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome","volume":"348","author":"Srivastava","year":"1990","journal-title":"Nature"},{"key":"R7-20250219","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1158\/1078-0432.CCR-06-2545","article-title":"Transcriptional functionality of germ line p53 mutants influences cancer phenotype","volume":"13","author":"Monti","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R8-20250219","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R9-20250219","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1200\/JCO.2008.16.6959","article-title":"Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations","volume":"27","author":"Gonzalez","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-20250219","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/humu.22559","article-title":"Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome","volume":"35","author":"Kamihara","year":"2014","journal-title":"Hum Mutat"},{"key":"R12-20250219","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1136\/jmg.40.4.e34","article-title":"Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?","volume":"40","author":"Martin","year":"2003","journal-title":"J Med Genet"},{"key":"R13-20250219","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10689-012-9557-z","article-title":"Routine TP53 testing for breast cancer under age 30: ready for prime time?","volume":"11","author":"McCuaig","year":"2012","journal-title":"Fam Cancer"},{"key":"R14-20250219","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/humu.24152","article-title":"Specifications of the ACMG\/AMP variant interpretation guidelines for germline TP53 variants","volume":"42","author":"Fortuno","year":"2021","journal-title":"Hum Mutat"},{"key":"R15-20250219","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"R16-20250219","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","article-title":"Mutational processes shape the landscape of TP53 mutations in human cancer","volume":"50","author":"Giacomelli","year":"2018","journal-title":"Nat Genet"},{"key":"R17-20250219","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","article-title":"A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol Cell"},{"key":"R18-20250219","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1038\/sj.onc.1208839","article-title":"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library","volume":"24","author":"Kawaguchi","year":"2005","journal-title":"Oncogene"},{"key":"R19-20250219","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"R20-20250219","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R21-20250219","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"suppl 1","key":"R22-20250219","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"K\u00f6bel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R23-20250219","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Yemelyanova","year":"2011","journal-title":"Mod Pathol"},{"key":"R24-20250219","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","article-title":"The TP53 database: transition from the International Agency for Research on Cancer to the US National Cancer Institute","volume":"29","author":"de Andrade","year":"2022","journal-title":"Cell Death Differ"},{"key":"R25-20250219","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CCO.0000000000000423","article-title":"Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome","volume":"30","author":"Amadou","year":"2018","journal-title":"Curr Opin Oncol"},{"key":"R26-20250219","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R27-20250219","doi-asserted-by":"crossref","first-page":"836937","DOI":"10.3389\/fonc.2022.836937","article-title":"Breast Cancer phenotype associated with Li-Fraumeni syndrome: a Brazilian cohort enriched by TP53 p.R337H carriers","volume":"12","author":"Sandoval","year":"2022","journal-title":"Front Oncol"},{"key":"R28-20250219","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1947601911413466","article-title":"Li-fraumeni syndrome","volume":"2","author":"Malkin","year":"2011","journal-title":"Genes Cancer"},{"key":"R29-20250219","doi-asserted-by":"crossref","first-page":"16614","DOI":"10.1038\/s41598-020-73282-y","article-title":"Frequency of the TP53 R337H variant in sporadic breast cancer and its impact on genomic instability","volume":"10","author":"Mathias","year":"2020","journal-title":"Sci Rep"},{"key":"R30-20250219","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/cjp2.133","article-title":"Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early-onset breast cancer (COPE study)","volume":"5","author":"Packwood","year":"2019","journal-title":"J Pathol Clin Res"},{"key":"R31-20250219","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41379-020-0610-4","article-title":"Histopathologic features of breast cancer in Li-Fraumeni syndrome","volume":"34","author":"Kuba","year":"2021","journal-title":"Mod Pathol"},{"key":"R32-20250219","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/90.15.1138","article-title":"Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations","volume":"90","author":"Lakhani","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R33-20250219","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jmg.2010.078113","article-title":"A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations","volume":"47","author":"Wilson","year":"2010","journal-title":"J Med Genet"},{"key":"R34-20250219","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","article-title":"Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort","volume":"133","author":"Masciari","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"R35-20250219","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncr.26377","article-title":"Early onset HER2-positive breast cancer is associated with germline TP53 mutations","volume":"118","author":"Melhem-Bertrandt","year":"2012","journal-title":"Cancer"},{"key":"R36-20250219","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-012-2375-z","article-title":"Prevalence of germline TP53 mutations in HER2+ breast cancer patients","volume":"139","author":"Rath","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"R37-20250219","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/humu.24060","article-title":"Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG\/AMP guidelines","volume":"41","author":"Fortuno","year":"2020","journal-title":"Hum Mutat"},{"key":"R38-20250219","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s12885-018-4613-1","article-title":"Mutant p53 gain of function induces HER2 over-expression in cancer cells","volume":"18","author":"Rom\u00e1n-Rosales","year":"2018","journal-title":"BMC Cancer"},{"key":"R39-20250219","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10689-015-9779-y","article-title":"The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers","volume":"14","author":"Fitarelli-Kiehl","year":"2015","journal-title":"Fam Cancer"},{"key":"R40-20250219","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1006425809069","article-title":"P53 protein accumulation in non-invasive lesions surrounding p53 mutation-positive invasive breast cancers","volume":"65","author":"Done","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"R41-20250219","first-page":"67","article-title":"p53 mutations are confined to the comedo-type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data","volume":"71","author":"O\u2019Malley","year":"1994","journal-title":"Lab Invest"},{"key":"R42-20250219","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1038\/sj.onc.1204621","article-title":"Relative frequency and morphology of cancers in carriers of germline TP53 mutations","volume":"20","author":"Birch","year":"2001","journal-title":"Oncogene"},{"key":"R43-20250219","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1245\/s10434-020-08480-z","article-title":"Germline genetic mutations in a multi-center contemporary cohort of 550 phyllodes tumors: an opportunity for expanded multi-gene panel testing","volume":"27","author":"Rosenberger","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R44-20250219","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00428-013-1439-8","article-title":"A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil","volume":"463","author":"Giacomazzi","year":"2013","journal-title":"Virchows Arch"},{"key":"R45-20250219","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/annonc\/mdt287","article-title":"Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications","volume":"24","author":"Montemurro","year":"2013","journal-title":"Ann Oncol"},{"key":"R46-20250219","doi-asserted-by":"crossref","first-page":"108822","DOI":"10.1016\/j.celrep.2021.108822","article-title":"Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer","volume":"34","author":"Yang","year":"2021","journal-title":"Cell Rep"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:00:54Z","timestamp":1739952054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002338","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}